Skip to main content
. Author manuscript; available in PMC: 2019 Mar 28.
Published in final edited form as: J Control Release. 2018 Jan 31;274:24–34. doi: 10.1016/j.jconrel.2018.01.028

Figure 6.

Figure 6

A. Development of ~20 nm nanodics and co-encapsulated with antigen and adjuvant and due to smaller size nanodisc has faster access to lyphatic vessel, thus generating stronger immue responses compared to conventional peptide antigen. B. Higher expression of antigen (right panel) in case of nanodisc treated dendritic cell as compared to free peptide form of antigen (left panel). C. Complete rejection of tumor in sHDL-Ag/CpG (nanodics) vaccinated mice injected with B16Ova cancer cells. D. The strong activation of T-cell in sHDL-Ag/CpG vaccinated mice is the main reason for anti-tumor immune responses. images were reproduced from ref. [86]